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ultiple neurochemical pathways are involved in
the pathology of Alzheimer’s disease (AD).The follow-
ing factors have been implicated in the development of
AD:β-amyloid;tau proteins;apolipoprotein E (APOE);
degeneration of cholinergic,serotonergic,and dopamin-
ergic neurons;oxidative damage;inflammation;estrogen
deficiency;and glutamatergic neurotransmission.
Neurochemical pathways for AD
β-Amyloid
It has been suggested that deposits of β-amyloid proteins
appear to be the earliest morphological changes in the
formation of neuritic plaques.
1,2These plaques ultimately
lead to the death and destruction of surrounding axons
and dendrites.
Tau proteins
Tau proteins are highly phosphorylated microtuble pro-
teins that form neurofibrillary tangles.These abnormal
filaments form either parallel bundles or randomly
arranged paired helical filaments that extend to the den-
dritic processes.
2These tangles lead to dysfunction and
degeneration of nerve cells.
Apolipoprotein E
APOE is a cholesterol transport protein that has been
linked to late-onset familial and sporadic AD.
1-4The gene
for this protein is found on chromosome 19 and is inher-
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Alzheimer’s disease is a progressive, debilitating form of
dementia affecting more than 18 million people worldwide.
Without a cure, many patients and their families must turn
to long-term care institutions during the later stages of the
disease. Our current treatments only delay progression and
help control behavioral symptoms. In recent years, research
within this field has expanded to include many clinical trials
on potential drug therapies. However, despite the numer-
ous studies, the enigma of this disease remains. It is difficult,
yet necessary, to stay abreast of emerging information that
may warrant changes in current therapy. Rationale for com-
bination therapy becomes evident as we review the multi-
ple neurochemical pathways common to the disease. This
paper will review available information on Alzheimer’s dis-
ease pharmacotherapy, and evaluate data on the use of
combination drug therapy. Individual efficacy, possible syn-
ergistic effects, and the safety of combination therapy will
also be addressed.
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1,2
The ApoE E4 gene has been correlated with an
increased risk and earlier onset of AD.
2
Degeneration of cholinergic, serotonergic, and 
dopaminergic neurons
It is known that normal memory functions involve cholin-
ergic systems and that cholinergic deficiency is present in
AD. Choline acetyltransferase activity and acetyltrans-
ferase are significantly reduced in the cerebral cortex,hip-
pocampus, and amygdala in AD patients.
2 Many of our
current treatments are attempts to increase cholinergic
neurotransmission.Acetylcholine precursors,cholinergic
agonists,and acetylcholinesterase inhibitors have all been
used in the treatment of AD.
2 Serotonergic and dopamin-
ergic neurotransmission is decreased in AD,hence pro-
moting the idea that antidepressants and antipsychotics
are beneficial in treatment.
Oxidative damage
Oxidative damage is also believed to play an important
role in AD.Free carbonyls and thiobarbituric acid–reac-
tive products are significantly increased in AD brain tis-
sue.
2,5,6 Plaques and tangles have also been shown to dis-
play immunoreactivity to antioxidant enzymes.A number
of medications appear to counteract oxidative stress.
Vitamin E (an antioxidant) and selegiline (an inhibitor of
monoamine oxidase B and thought to act as a free radi-
cal scavenger) have both been used in AD treatment.
2,7
Both were found to delay time of death,institutionaliza-
tion, and loss of the ability to perform the activities of
daily living.
2,7 Gingko biloba has also been shown to have
antioxidant properties and will be explored later in this
paper.
Estrogen
Studies have shown that estrogen loss predisposes to cog-
nitive decline and neuronal degeneration.
1,2 Several epi-
demiological studies have indicated that women taking
estrogen supplementation have a lower risk of AD than
those who do not.
8-10At least one multicenter,random-
ized,double-blind,placebo-controlled study is underway
to determine whether estrogen can delay the onset of
AD and memory loss in women 65 years of age or older
with a family history of AD (Sano M,personal commu-
nication).The role of estrogen in cholinergic pathways
has also been demonstrated by basic research.For exam-
ple,neuronal choline uptake and choline acetyltranferase
have been shown to be reduced in the brains of ovariec-
tomized female rats.
2
Glutamatergic neurotransmission
Glutamate is believed to be the major fast excitatory
neurotransmitter in the brain.
11 Glutamate activates three
major classes of receptors,and its activation of N-methyl-
D-aspartate (NDMA) receptors plays a critical role in
learning and memory.
12
Cholinergic pathways: donepezil
All of the acetylcholinesterase inhibitors act by inhibiting
the breakdown of acetylcholine,thus allowing the neuro-
transmitter to continue its action at the synapse.Donepezil,
a reversible cholinesterase inhibitor, has been shown to
have a greater specificity for acetylcholinesterase and a
longer duration of activity than tacrine or physostigmine.
13
In a double-blind,placebo-controlled trial of donepezil,
AD patients were randomly assigned to placebo,5 mg,or
10 mg donepezil for 24 weeks followed by a 6-week,single-
blind placebo washout.The primary measure of efficacy
was the Alzheimer’s Disease Assessment Scale-Cognitive
subscale (ADAS-Cog).Cognitive function improved in the
5 and 10 mg donepezil groups compared with the placebo
groups at 12,18,and 24 weeks.The washout period showed
a decline in ADAS-Cog score in both groups.
13
Emerging treatments
Many of the latest treatments for AD do not involve
cholinergic pathways. For example, Ginkgo biloba is
being investigated for the prevention of oxidative dam-
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Selected abbreviations and acronyms
ADAS-Cog Alzheimer’s Disease Assessment
Schedule–Cognitive Section
AD Alzheimer’s disease
CGIC Clinical Global Impression of Change
FAST Functional Assessment Staging
GDS Global Deterioration Scale
MMSE Mini-Mental State Examination
NMDA N-methyl-D-aspartate
NSAID nonsteroidal anti-inflammatory drugage and inflammation.Nonsteroidal anti-inflammatory
drugs (NSAIDs) are also being used to treat the inflam-
matory processes of AD. Atypical antipsychotics and
selective serotonin reuptake inhibitors (SSRIs) are
potential treatments for the serotonergic and dopamin-
ergic deficiencies seen in AD.
Ginkgo biloba
A number of trials have evaluated the efficacy of
Ginkgo biloba in the treatment of AD.In a study by Le
Bars et al,
14 120 mg Ginkgo biloba extract was given in a
52-week,double-blind,placebo-controlled investigation;
309 patients were randomized with 202 patients com-
pleting the study. Inclusion criteria selected patients 
with mild-to-moderate dementia, Mini-Mental State
Examination (MMSE) scores ranging from 9 to 26,and
Global Deterioration Scale (GDS) scores of 3 to 6.The
ADAS-Cog, Geriatric Evaluation by Relative’s Rating
Instrument (GERRI), and Clinical Global Impression
of Change (CGIC) were used as primary outcome mea-
sures.
14 Participants on Ginkgo biloba had a slight
improvement from baseline on the ADAS-Cog, while
the placebo group showed continued worsening,with an
increased score from 1.4 at 26 weeks to 2.1 at end point.
The mean treatment difference of -2.4 points further
favored the Ginkgo biloba group.
14
Conversely,not all studies have shown Ginkgo biloba to
be efficacious in the treatment of AD. In a 24-week,
double-blind treatment trial,participants were random-
ized to either 160 mg/day Ginkgo biloba, 240 mg/day
Ginkgo biloba,or placebo.
15There were 214 participants
with mild-to-moderate dementia as a result of AD,vas-
cular insufficiency,or age-associated memory impairment.
Outcome measures included neuropsychological testing,
digit memory span,and verbal learning.Intention-to-treat
analysis showed no effect on any of the outcome mea-
sures for participants assigned to Ginkgo biloba com-
pared with placebo for the entire 24-week period.After
12 weeks of treatment,the combined high dose and usual
dose groups performed only slightly better with regard to
self-reported activities of daily life compared with the
placebo groups.No beneficial effects of a higher dose or
a prolonged duration of Ginkgo biloba treatment were
found.
Ginkgo biloba has also been compared with cholinesterase
inhibitors in the treatment of AD.In one study comparing
the efficacy of four cholinesterase inhibitors and Ginkgo
biloba,the ADAS-Cog scale was used to measure the dif-
ferences in effects after 6 months of treatment.
16 After
accounting for the differing degrees of dementia in the
various studies and dropout rates, no major differences
were seen in efficacy between the four cholinesterase
inhibitors and Ginkgo biloba.
16
Nonsteroidal anti-inflammatory drugs
NSAID use is thought to protect against the inflamma-
tory reactions that are known to be present in the neu-
rons of patients with AD.A large amount of positive data
has been reported on the use of NSAIDs in the treat-
ment of AD.In one study,data were collected from 1648
AD participants in two identical,26-week,multicenter
pharmaceutical trials to examine the distribution of base-
line ADAS-Cog scores in relation to certain demographic
and clinical variables. ADAS-Cog total scores and
NSAID use were evaluated for potential association.
NSAID use was associated with higher cognitive perfor-
mance (ADAS-Cog scores of 26.4±10.6 compared with
28.5±11.0;P=0.0003).
17 Diclofenac,an NSAID,has also
been evaluated for the treatment of AD.Scharf et al eval-
uated the safety and efficacy of diclofenac in combina-
tion with misoprostol in patients with AD in a 25-week,
randomized,double-blind,placebo-controlled trial
18:41
participants were enrolled and 27 completed the study.
Selection criteria included mild-to-moderately severe
AD and MMSE scores of 12 to 23. Primary outcome
measures included the ADAS-Cog, GDS, and CGIC.
There were no significant differences between the
diclofenac/misoprostol and placebo groups. However,
trends toward slower decline in the diclofenac/miso-
prostol group were noted. The authors cited possible
explanations for the absence of significant differences as
low sample size, failure of the placebo group to show
expected decline,and insufficient observation time.
18
Glutamatergic pathways
Glutamatergic neurotransmission has been implicated in
both the symptomatology and pathology of a variety of
neurological conditions.
19 In pathological conditions,such
as AD,sustained release of glutamate leads to moderate
activation of NMDA receptors.As a result,magnesium
is displaced from the NDMA receptor and there is a con-
tinuous influx of calcium into the cell.This chronic exci-
totoxicity results in a cognitive deficit due to decrease in
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insult.
19,20 NMDA receptor antagonists block the influx of
calcium resulting in a reduction in intracellular calcium.
Consequently, the noise is reduced and the signal is
processed.Memantine,an NMDA receptor antagonist,
is currently being investigated in the treatment of AD.
Memantine
In a 28-week,double-blind treatment trial comparing 20
mg/day memantine with placebo,252 participants were
randomized and 181 completed the study. Participants
had MMSE scores between 3 and 14,GDS scores of 5 or
6, and Functional Assessment Staging (FAST) greater
than 6a.There was also a 24-week open-label extension
for 175 participants who completed the 28-week study.
The CIBIC-plus (Clinicians’ Interview-based Impression
of Change–plus), ADAS-Activities of Daily Living,
Severe Impairment Battery (SIB),and FAST were used
to measure outcome.
21 Participants on memantine had a
slower rate of decline than those receiving placebo.
During the open-label extension,participants switched
to memantine showed a more gradual decline compared
with the first 28 weeks of placebo treatment.
22
Serotonergic and dopaminergic pathways: 
implications for treatment of 
behavioral disturbances
Newer antipsychotics,such as risperidone,are combined
serotonin and dopamine antagonists.Most of the newer
antipsychotics exhibit strong antagonistic affinity for 
the serotonin (5-hydroxytryptamine) receptor 5-HT2.
22
Risperidone has been shown to be efficacious in the treat-
ment of psychosis and behavioral disturbances associated
with dementia.Katz et al
23 evaluated 625 participants in a
12-week,double-blind treatment study comparing 0.5 to
2 mg/day of risperidone to placebo. Participants had a
diagnosis of AD and/or vascular dementia (73% had
AD),FAST scale score of ≥4,MMSE of ≤23,Behavioral
Pathology in Alzheimer’s Disease (BEHAVE-AD) rat-
ing of ≥8 and a global rating of ≥1. Outcome measures
included BEHAVE-AD, Cohen-Mansfield Agitation
Inventory (CMAI),and CGI.
23 Significant reductions in
BEHAVE-AD total scores,psychosis,and aggressiveness
subscale scores were seen in patients receiving 1 and 2
mg/day risperidone,compared with patients on placebo.
Adverse events were more commonly seen in the 2
mg/day group and included extrapyramidal symptoms,
somnolence,and mild peripheral edema.
23
Antidepressants such as sertraline exert their main
effects via the serotonergic system.Sertraline has been
evaluated for its efficacy in the treatment of depression
in AD (Lyketsos C,personal communication).Twenty-
nine patients were assessed with the Neuropsychiatric
Inventory (NPI).Average baseline scores were 7.3.After
12 weeks of treatment,patients on sertraline had a reduc-
tion in scores by 2.78 points, while the placebo group
scores were increased by 0.18 points.
Cholinergic pathways:
implications for treatment of 
behavioral disturbances
Acetylcholinesterase inhibitors have been shown to ben-
efit the cognitive,functional,and behavioral symptoms
of patients with AD.For example,one study evaluated
978 patients with mild-to-moderate AD treated with slow
dose escalation of galantamine.
24 After 4 weeks of
placebo,patients were randomized to one of four treat-
ment groups:placebo or galantamine escalated to final
doses of 8,16,or 24 mg/day.At 5 months,both the 16 and
24 mg/day groups showed very little change from base-
line,while the placebo group scores deteriorated.As a
result, the 16 and 24 mg/day groups exhibited signifi-
cantly better NPI total scores as compared to placebo
(P<0.05). Improvements were also seen in the ADAS-
Cog and CIBIC-plus in the 16 and 24 mg/day groups.
24
Combination therapy: 
rationale, efficacy, and safety
A potential treatment regimen may be developed based
on the stages of AD.
•The latent stage,which may last for several decades,exists
among individuals at known genetic risk of late-life AD.
25
These patients may show changes in functional abilities,
early neuroanatomic changes,and regional hypometab-
olism in temporal and parietal lobes in their middle life.
25
During this stage, neuroprotection with NSAIDs,
NMDA receptor antagonists,and estrogen may slow or
attenuate progress and prove beneficial.
• During the prodromal stage, early cognitive symptoms
appear, and as damage increases substantial impair-
ment develops.
25Treatment interventions in this stage
may slow progression from mild symptoms to disabling
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this stage of the disease.
• During the symptomatic stage, the goal is to improve
existing cognitive functions and prevent current symp-
toms from worsening.
25 Medications that may be bene-
ficial during this stage include Ginkgo biloba,NMDA
receptor antagonists,antipsychotics,and antidepressants.
Treatment strategies for the immediate future should
include therapy with some or all of the following com-
pounds:acetylcholinesterase inhibitors,Ginkgo biloba,
NSAIDs,NMDA receptor antagonists,atypical antipsy-
chotics,and SSRIs.One study is currently investigating
whether the concurrent use of an atypical antipsychotic
(risperidone,olanzapine,or quetiapine) and galantamine
increases the incidence of adverse events associated with
either class of drug.
26 Subjects from the following multi-
center,double-blind,placebo-controlled studies of galan-
tamine in the USA were included: GAL-USA-1 and
GAL-USA-10. Only the subjects that were either on
galantamine 16 or 24 mg, or placebo were included.
Subjects who used conventional antipsychotics and sub-
jects who took atypical antipsychotics only during screen-
ing were excluded. Specific adverse events outcomes
included the following:falls,peripheral edema,rhinitis,
somnolence,urinary tract infection,and extrapyramidal
symptoms.These adverse events have been described in
previous studies of atypical antipsychotic treatment in
older adults.
23,24,27,28
The risk of adverse events linked to atypical antipsy-
chotics and acetylcholinesterase inhibitors was analyzed.
There was no overall statistical difference between drug
groups for falls, rhinitis, or urinary tract infections.
Further, there were no reports in peripheral edema.
When an atypical antipsychotic plus galantamine was
compared with an atypical antipsychotic only,there was
no difference in extrapyramidal side effects (odds ratio
[OR]=1.04).There was a higher risk of somnolence,how-
ever, in the atypical antipsychotic plus galantamine
group, but it was not significant (OR=1.86; P=0.305).
When an atypical antipsychotic plus galantamine was
compared with galantamine only, the risk of any gas-
trointestinal adverse effect was lower in the atypical
antipsychotic plus galantamine group,but not significant
(OR=0.75; P=0.227). Both nausea and vomiting were
lower in the atypical antipsychotic plus galantamine
group. Nausea was significantly lower (OR=0.42).
Vomiting,however,was noted to be lower in the atypical
antipsychotic plus galantamine group (OR=0.53),but not
significantly (P=0.147).There was no overall statistical
difference between the two groups for diarrhea.
Another study analyzed the efficacy and safety of the
combination of donepezil and sertraline on behavioral
and cognitive symptoms of AD.
29 Participants in this trial
were all given 8 weeks of open-label donepezil and were
then randomized to double-blind donepezil and sertra-
line or donepezil and placebo.The goal was 240 partici-
pants at 24 sites.This study showed no clear beneficial
effects for the combination.Secondary analysis on this
data is currently ongoing.
Adverse events were noted to be similar in the two
groups
29:in 87.1% of patients with donepezil plus sertra-
line and 81.7% with donepezil plus placebo. Serious
adverse events occurred in 8.9% of patients on donepezil
plus sertraline and 5.8% of patients on donepezil plus
placebo.Discontinuations occurred in 11.3% on donepezil
plus sertraline and 9.2% on donepezil plus placebo.
Adverse effects related to the digestive system were more
common in the donepezil plus sertraline group at 49.2%,
compared with 31.7% in the donepezil plus placebo group.
The majority of digestive system adverse events were mild.
Another potential combination treatment involves the
concurrent treatment with acetylcholinesterase inhibitors
and NMDA antagonists.One study has evaluated the effi-
cacy of donepezil alone versus donepezil and memantine
in a double-blind,placebo-controlled trial.
30A total of 403
moderately to severely affected AD patients were enrolled
in this 6-month trial.At the end of 28 weeks during the
double-blind phase, combination therapy showed
improvement in the CIBIC-plus score compared with
donepezil alone and placebo.Both donepezil and placebo
showed a decline in scores,with placebo treatment having
the greatest.
Conclusion
Combination pharmacotherapy offers optimal manage-
ment of AD symptoms by targeting various neurochem-
ical pathways. A few studies have found combination
pharmacotherapy to be both efficacious and safe in AD
patients.More research is needed in the area to further
define the benefits as well as the pitfalls of combination
pharmacotherapy in this fragile population. ❏
Support for this work was provided by the National Institute on Aging by
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Farmacoterapia combinada en la
Enfermedad de Alzheimer
La Enfermedad de Alzheimer es una demencia de
tipo progresivo y debilitante que afecta a más de
18 millones de personas en el mundo. Al no dispo-
ner de tratamiento curativo, muchos pacientes y sus
familias deben tomar contacto con establecimien-
tos de estancia prolongada durante las etapas fina-
les de la enfermedad. Los tratamientos actuales
sólo retardan la progresión de los síntomas y ayu-
dan al control conductual. En los últimos años la
investigación en este campo se ha incrementado y
se han incluido muchos ensayos clínicos de poten-
ciales fármacos. Sin embargo, a pesar de los nume-
rosos estudios, persiste el enigma de esta enferme-
dad. Resulta difícil, aunque es necesario, estar al día
sobre la información emergente que pueda justifi-
car cambios en los tratamientos actuales. El funda-
mento de la terapia combinada resulta evidente al
revisar las múltiples vías neuroquímicas comunes
para esta enfermedad. Este artículo revisará la
información disponible sobre la farmacoterapia de
la Enfermedad de Alzheimer y evaluará los datos
de la asociación de medicamentos. También serán
tratados la eficacia individual, los posibles efectos
sinérgicos y la seguridad de la terapia combinada.
Association médicamenteuse dans la mala-
die d’Alzheimer
La maladie d’Alzheimer est une forme de démence
progressive, débilitante, qui affecte plus de 18 mil-
lions d’individus dans le monde. En l’absence d’un
traitement curatif, lors des phases ultérieures de la
maladie, de nombreux patients et leur famille doi-
vent se tourner vers des établissements de long
séjour. Les traitements actuels ne font seulement que
retarder la progression et contribuer au contrôle des
symptômes comportementaux. Ces dernières années,
la recherche dans ce domaine s’est élargie pour
inclure de nombreux essais cliniques sur des traite-
ments médicamenteux potentiels. Cependant, en
dépit des nombreuses études, l’énigme posée par
cette maladie demeure. Il est difficile, mais pourtant
nécessaire d’être au fait des informations émer-
gentes susceptibles d’entraîner des changements
dans le traitement actuel. Les arguments pour une
association thérapeutique deviennent évidents au vu
des multiples voies neurochimiques communes à la
maladie. Cet article passe en revue les informations
disponibles sur la pharmacothérapie de la maladie
d’Alzheimer et évalue les données sur l’utilisation
d’une association médicamenteuse. Efficacité indivi-
duelle, possibles effets synergiques et tolérance de
l’association thérapeutique sont aussi évoqués.
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